Prof. Chris Mason MBBS, PhD, FSB, FRCSI, FRCS

Co-Founder and CEO, LRMN

Professor of Regenerative Medicine Bioprocessing at
Advanced Centre for Biochemical Engineering, University College London

Chris Mason is internationally recognized to be at the forefront of the emerging field of cell therapy translation and commercialization. He has a background in commerce, a Clinical Sciences Degree (Imperial College), a Medical Degree (St. Thomas’s Hospital), a PhD in tissue engineering (UCL), Fellow of the Royal College of Surgeons and Fellow of the Society of Biology.

Current responsibilities include: Chair of the
BIA Cell Therapy & Regenerative Medicine Industry Group, Senior Editor of Regenerative Medicine journal, Director of the London Regenerative Medicine Network, Trustee of the UK Stem Cell Foundation, member of the Biologicals and Vaccines Expert Advisory Group of the Commission on Human Medicines and member of the United States Pharmacopeia Monographs - Biologics & Biotechnology Expert Committee. Chris is on a number of national and international committees, working groups and initiatives related to the academic, clinical and commercial advancement of cell-based therapies and tissue engineering. In May 2012, he became the first President of the Regenerative Medicine Coalition. He is a Senior Partner at Proteus Venture Partners, has a broad range of expertise in commercial consultancy and is on the Scientific Advisory Boards of several companies based North America.

Chris Mason Passport Size 45 35 mm

Stephen Minger, PhD

Director, LRMN

Director at SLM Blue Skies Innovations Ltd

Stephen Minger is a well-known and respected member of the regenerative medicine community, as both a researcher and thought-leader who has contributed significantly to regulatory and policy issues in the field. Prior to SLM Blue Skies Innovations Ltd, Stephen was Global Head of R&D, Cell Technologies for GE Healthcare and was responsible for strengthening GE’s rapidly growing capability in the development of enabling technologies for cell-based drug research and cell therapies.

Prior to joining GE in September 2009, he was Director of the Stem Cell Biology Laboratory and a Senior Lecturer at the Wolfson Centre for Age Related Diseases at King's College London, where he pioneered his work with a wide range of somatic stem cell populations, resulting in being jointly awarded one of the first two licenses granted by the UK Human Fertilisation and Embryology Authority for the derivation of human ES cells. He has a PhD in Pathology (Neurosciences) from the Albert Einstein College of Medicine, was a post-doctoral fellow at the University of California, San Diego, and was an Assistant Professor in Neurology at The University of Kentucky Medical School.


James Lawford Davies

Director, LRMN

Partner at

James is a solicitor specialising in the law and regulation relating to reproductive and genetic technologies, human tissue and cells, and related research.  He has advised widely on the regulatory and commercial issues relating to stem cell research, including cell nuclear replacement, human-animal hybrids research, import and export, and the implications of EU law. James advises a large number of clinics and research centres licensed by the Human Fertilisation and Embryology Authority (HFEA) and has been involved in most of the leading cases relating to assisted reproduction, embryo and hES cell research. He was described by the Financial Times as "the world leading expert" in embryonic stem cell research in their 2009 Innovative Lawyers Report.

James qualified as a solicitor in 2000, has held positions at Clifford Chance LLP and Lawford Davies Denoon, and in July 2015 joined Hempsons. In addition to his private practice, James is Honorary Lecturer in Law and Medicine at University College London.


Emily Culme-Seymour, PhD

Director, LRMN

External Strategy Manager, Gene Therapy at GSK Rare Diseases Unit

Emily is External Strategy Manager, Gene Therapy at the GSK Rare Diseases Unit. She has a background in Chemistry and Biochemical Engineering, looking at engineering growth substrates for pluripotent stem cell bioprocessing during her PhD (University College London). As a Director of the LRMN, she previously represented the network on a number of UK and EU consortium projects looking at cell therapy technologies and business modelling.

As well as her role at GSK, Emily sits on the International Society for Cell Therapy's Executive Committee as Global Treasurer and is a Scientific Advisor at Proteus Venture Partners, a co-founder of the ATMP Manufacturing Community, and a member of the UK BIA's Cell Therapy Advisory Committee, as well as a member of the American, European, and British Societies for Gene and Cell Therapy.


We are very fortunate to have a dedicated team of volunteer helpers and technical experts, who work in close association with us at all our events as well as on our research and out-reach projects. The majority of our team are PhD and EngD students in the UCL Advanced Centre for Biochemical Engineering, carrying out translational research into cell therapy bioprocessing, and are therefore expertly qualified to help support the LRMN in its diverse range of multi-stakeholder activities.